The new inhaler replaces Trixeo Aerosphere’s existing gas propellant with a low global warming-potential alternative.

Patients with COPD and chronic hypercapnic respiratory failure on noninvasive ventilation report similar quality of life ...

During monsoon season, respiratory infections, allergies, and chronic respiratory disorders including asthma and chronic ...

Across four prospective U.S. cohorts, 4.5% of those 18-49 years old met criteria for COPD, defined as spirometric airflow ...

While numerous studies have assessed how much people with chronic obstructive pulmonary disease (COPD) walk, few have explored how they walk, especially in unsupervised, ...

The pivotal Phase IIb ALIENTO study met its primary endpoint and showed that astegolimab reduced the annualized exacerbation rate (AER) by a statistically significant 15.4% at 52 weeks, when given ...

Roche’s hopes of getting its chronic obstructive pulmonary disease (COPD) drug astegolimab to regulators this year have taken ...

The path to market for Roche’s astegolimab became more uncertain after the investigational antibody failed to significantly ...

Urine VOCs are linked to COPD risk and inflammation in NHANES data, suggesting potential for non-invasive screening with ...

The pivotal phase IIb ALIENTO study met the primary endpoint of a statistically significant reduction in the annualised exacerbation rate (AER) at 52 weeks when astegolimab was given every two weeksTh ...

Microsoft and our third-party vendors use cookies to store and access information such as unique IDs to deliver, maintain and improve our services and ads. If you agree, MSN and Microsoft Bing will ...

Astegolimab from Roche's Genentech fails phase 3 COPD trial, reflecting challenges in monoclonal antibody treatment for the ...